Search

Learn more about olaratumab, a promising drug that has been shown to extend survival for people with advanced soft tissue sarcoma — particularly leiomyosarcoma — by nearly a year in a phase II clinical trial.

… Monday, June 13, 2016 Summary A phase II clinical trial for sarcoma has shown that the targeted drug therapy olaratumab extends survival by nearly a year for people with advanced disease. The study’s lead investigator says the results are “unprecedented” for this rare disease, which currently has very

Results from a study of women with breast and ovarian cancer show surprisingly low rates of genetic testing.

… Tuesday, July 16, 2019 Summary A recent study in the Journal of Clinical Oncology found that only a quarter of women with breast cancer and a third of women with ovarian cancer had undergone genetic testing. MSK experts say these numbers are surprisingly low. A lot has changed since the BRCA genes were

Over the last seven and a half decades, researchers at the Sloan Kettering Institute have made important contributions to the fundamental understanding of human biology, as well as driven practice-changing innovations in the treatment of cancer.

… Friday, May 19, 2023 When the Sloan Kettering Institute opened its doors on Friday, April 16, 1948, an Associated Press wire story announced: “The world’s greatest cancer center opened here today.” And over the last seven and a half decades, institute researchers have made important contributions to

Brittany Woods, who is completing her doctoral work in the laboratory of physician-scientist Ross Levine, has received a pilot award from the National Cancer Institute that supports outstanding PhD candidates

… Wednesday, October 19, 2016 Brittany Woods , a fifth-year Gerstner Sloan Kettering student, recently received the National Cancer Institute’s Predoctoral to Postdoctoral Fellow Transition Award . This pilot award will support outstanding PhD candidates as they complete their dissertation research and

Doctors and nurses with Memorial Sloan Kettering’s Plastic and Reconstructive Surgical Service have developed new, simplified models to better predict and prevent breast cancer-related lymphedema.

… Thursday, July 27, 2023 Doctors and nurses with  Memorial Sloan Kettering’s Plastic and Reconstructive Surgical Service have developed new, simplified models to better predict and prevent  breast cancer-related lymphedema, an uncomfortable side effect that develops in the months following surgery. Lymphedema

Learn about results from a clinical trial that found blood tests can help predict which patients with large B cell lymphoma are likely to benefit from the targeted therapy glofitamab (Columvi).

… Monday, December 11, 2023 There is encouraging news about using a blood test to determine which patients with aggressive large B cell  lymphoma were most likely to benefit from having the drug glofitamab (Columvi™) added to their treatment. Results from a phase 2 clinical trial (research study) were

Dose-dense chemotherapy calls for less time between doses compared with a standard treatment plan.

… Wednesday, December 6, 2017 VIDEO | 01:09 Larry Norton Explains the Development of Dose-Dense Chemotherapy and His Hopes for the Future Hear medical oncologist Larry Norton describe how dose-dense chemotherapy was developed for breast cancer and his hopes for the future of research. Video Details Summary

How cryo-electron microscopy is providing scientists at MSK with an unprecedented view of the wild and wiggly microcosm inside our cells.

… Friday, September 20, 2024 Boxy, sleek, and fronted with dark glass, it looks more like a 10-foot-tall wine fridge than a multimillion-dollar microscope. But this technological marvel is providing scientists at Memorial Sloan Kettering Cancer Center (MSK) with an unprecedented view of the wild and wiggly

A protein in blood vessels that plays a role in cancer metastasis is a promising target for delivering cancer drugs to tumors using nanoparticles.

… Thursday, July 7, 2016 Summary A major challenge in cancer treatment is making sure therapies destroy cancer cells without harming normal tissues. MSK researchers who are developing new types of nanotechnology to deliver cancer drugs have found a promising target — a protein called P-selectin that can

Results from the first phase I clinical trial of a new drug were presented at the American Association for Cancer Research’s meeting.

… Monday, April 1, 2019 Summary Early findings from the first phase I clinical trial of a drug called LOXO-195 were presented at the American Association for Cancer Research’s annual meeting in Atlanta. In November 2018, the US Food and Drug Administration approved the targeted therapy larotrectinib (Vitrakvi